- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
- Study: Vitamin D supplementation 'may contribute to better outcomes for many MS patients'
- Research: Global epilepsy therapeutics market to reach $4.5B by 2019
- FDA approves Lundbeck's Sabril in children
- Researchers discover how low vitamin D levels are linked to Autism Spectrum Disorder
FARMINGTON, Conn. – The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.
Global Information announced the availability of four research reports that analyze the global markets for treatments for syndromes of progressive ataxia and weakness disorders. According to GII, the global market for treatments was nearly $14 billion and is expected to reach $23.5 billion by 2017, after increasing at a five-year compound annual growth rate of 9.4%.
Key areas of growth include Friedrich's ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies, multiple sclerosis and amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.
Treatments for progressive weakness syndromes — a category that includes MS — are expected to total nearly $14.6 billion this year and $22.8 billion by 2017; MS treatments are expected to reach $19.5 billion by 2017.
Treatments for dementia and movement disorders, such as Parkinson's disease, are expected to reach $11.1 billion this year and $16.7 billion in 2017.